Morgan Stanley Reiterates Equal-Weight on Gilead Sciences, Maintains $86 Price Target
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Matthew Harrison has reiterated an Equal-Weight rating on Gilead Sciences (NASDAQ:GILD) and maintained a price target of $86.
July 11, 2023 | 1:14 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Morgan Stanley has reiterated an Equal-Weight rating on Gilead Sciences and maintained a price target of $86.
The reiteration of the Equal-Weight rating and price target by Morgan Stanley indicates that the analyst sees the stock as fairly valued at current levels. This is likely to have a neutral impact on the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100